TY - JOUR
T1 - ELMO1 deficiency enhances platelet function
AU - Patel, Akruti
AU - Kostyak, John
AU - Dangelmaier, Carol
AU - Badolia, Rachit
AU - Bhavanasi, Dheeraj
AU - Aslan, Joseph E.
AU - Merali, Salim
AU - Kim, Soochong
AU - Eble, Johannes A.
AU - Goldfinger, Lawrence
AU - Kunapuli, Satya
N1 - Publisher Copyright:
© 2019 by The American Society of Hematology.
PY - 2019/2/26
Y1 - 2019/2/26
N2 - Phosphatidylinositol 3-kinase is an important signaling molecule that, once activated, leads to the generation of phosphatidylinositol (3,4,5)-trisphosphate (PIP3). We performed a proteomic screen to identify PIP3-interacting proteins in human platelets. Among these proteins, we found engulfment and cell motility 1 (ELMO1), a scaffold protein with no catalytic activity. ELMO1 is expressed in platelets and interacts with active RhoG. However, the function of ELMO1 in platelets is not known. The focus of this study was to determine the function of ELMO1 in platelets utilizing ELMO12/2 mice. Platelet aggregation, granule secretion, integrin aIIbb3 activation, and thromboxane generation were enhanced in ELMO12/2 platelets in response to glycoprotein VI (GPVI) agonists but unaltered when a protease-activated receptor 4 agonist was used. The kinetics of spreading on immobilized fibrinogen was enhanced in ELMO12/2 platelets compared with wild-type (WT) littermate controls. This suggests that ELMO1 plays a role downstream of the GPVI and integrin aIIbb3 pathway. Furthermore, whole blood from ELMO12/2 mice perfused over collagen exhibited enhanced thrombus formation compared with WT littermate controls. ELMO12/2 mice showed reduced survival compared with control following pulmonary embolism. ELMO12/2 mice also exhibited a shorter time to occlusion using the ferric-chloride injury model and reduced bleeding times compared with WT littermate controls. These results indicate that ELMO1 plays an important role in hemostasis and thrombosis in vivo. RhoG activity was enhanced in ELMO12/2 murine platelets compared with WT littermate controls in response to GPVI agonist. Together, these data suggest that ELMO1 negatively regulates GPVI-mediated thrombus formation via RhoG.
AB - Phosphatidylinositol 3-kinase is an important signaling molecule that, once activated, leads to the generation of phosphatidylinositol (3,4,5)-trisphosphate (PIP3). We performed a proteomic screen to identify PIP3-interacting proteins in human platelets. Among these proteins, we found engulfment and cell motility 1 (ELMO1), a scaffold protein with no catalytic activity. ELMO1 is expressed in platelets and interacts with active RhoG. However, the function of ELMO1 in platelets is not known. The focus of this study was to determine the function of ELMO1 in platelets utilizing ELMO12/2 mice. Platelet aggregation, granule secretion, integrin aIIbb3 activation, and thromboxane generation were enhanced in ELMO12/2 platelets in response to glycoprotein VI (GPVI) agonists but unaltered when a protease-activated receptor 4 agonist was used. The kinetics of spreading on immobilized fibrinogen was enhanced in ELMO12/2 platelets compared with wild-type (WT) littermate controls. This suggests that ELMO1 plays a role downstream of the GPVI and integrin aIIbb3 pathway. Furthermore, whole blood from ELMO12/2 mice perfused over collagen exhibited enhanced thrombus formation compared with WT littermate controls. ELMO12/2 mice showed reduced survival compared with control following pulmonary embolism. ELMO12/2 mice also exhibited a shorter time to occlusion using the ferric-chloride injury model and reduced bleeding times compared with WT littermate controls. These results indicate that ELMO1 plays an important role in hemostasis and thrombosis in vivo. RhoG activity was enhanced in ELMO12/2 murine platelets compared with WT littermate controls in response to GPVI agonist. Together, these data suggest that ELMO1 negatively regulates GPVI-mediated thrombus formation via RhoG.
UR - http://www.scopus.com/inward/record.url?scp=85061992932&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85061992932&partnerID=8YFLogxK
U2 - 10.1182/bloodadvances.2018016444
DO - 10.1182/bloodadvances.2018016444
M3 - Article
C2 - 30787021
AN - SCOPUS:85061992932
SN - 2473-9529
VL - 3
SP - 575
EP - 587
JO - Blood advances
JF - Blood advances
IS - 4
ER -